Wall Street analysts expect that Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Rating) will report ($0.62) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Pyxis Oncology’s earnings, with the highest EPS estimate coming in at ($0.43) and the lowest estimate coming in at ($0.73). The firm is scheduled to issue its next earnings results on Monday, January 1st.
On average, analysts expect that Pyxis Oncology will report full-year earnings of ($2.83) per share for the current fiscal year, with EPS estimates ranging from ($3.72) to ($1.96). For the next fiscal year, analysts expect that the business will report earnings of ($2.69) per share, with EPS estimates ranging from ($3.49) to ($2.18). Zacks’ EPS averages are an average based on a survey of analysts that follow Pyxis Oncology.
Separately, Zacks Investment Research upgraded shares of Pyxis Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday, January 18th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $20.00.
Pyxis Oncology stock opened at $3.65 on Tuesday. The company has a 50 day moving average of $5.42. Pyxis Oncology has a twelve month low of $3.25 and a twelve month high of $19.00.
About Pyxis Oncology (Get Rating)
Pyxis Oncology, Inc, a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors.
- Get a free copy of the StockNews.com research report on Pyxis Oncology (PYXS)
- 3 Undervalued Easter Eggs to Watch For This Earnings Season
- Lululemon Rises On Wave Of Price Target Increases
- 3 Stellar Steel Stocks to Buy Now
- Is Nvidia (NASDAQ: NVDA) About To Rip Higher?
- The Top Is In For Infosys
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.